In light of the strong safety and PK data from otenaproxesul’s recent clinical PK/PD study, Antibe is upgrading the design of the upcoming Phase II trial. We're on track to initiate the trial next quarter with top-line results anticipated in calendar Q3 2024. #NSAID #Science

To simulate drug effects on the liver, we use DILIsym, a sophisticated software model widely used to predict liver safety, As predicted by DILIsym, our recent clinical PK/PD study showed all envisioned acute pain treatment regimens to be liver-safe. #OpioidCrisis #Inflammation

We're officially 2 weeks away from the first in a series of virtual events: "New Data and Formulation for Otenaproxesul" on Thurs, Jan 18th @ 11am EST. Have you registered yet? For more about this free event, visit our Events page on FB or LI! #OpioidCrisis $ATE.TO $ATBPF

With its Phase II trial set to launch this quarter, our next-generation NSAID aims to offer better GI safety while benefiting from a favorable cardiovascular profile. #ClinicalTrials #Science #ScienceNews #ScientificResearch #OpioidCrisis #Inflammation #Pain #NSAID #JPM2024

Our lead drug, otenaproxesul, is a non-opioid in clinical development for acute pain... targeting a $25 billion market that's seen no novel compounds introduced in 25 years. #OpioidCrisis #Inflammation #Pain #NSAID #DrugDevelopment #Science #DrugResearch

Join us for A Conversation with Antibe Therapeutics... learn about the benefits of otenaproxesul's new formulation, dive into Antibe's recently released data and Phase II planning, and explore the future of pain management. #Webinar #OpioidCrisis #Inflammation #Pain #NSAID

We're excited to announce that Antibe has been named to the 2024 #OTCQXBest50, a ranking of the top performing companies traded on the OTCQX Best Market. Selected from more than 575 companies, Antibe is the only biotech to achieve this designation. #OTC #OTCQX

Check out our new Corporate Presentation, including otenaproxesul's remaining path to approval on slide 28... find it at antibethera.com/investors/dash… #OpioidCrisis #Inflammation #Pain #NSAID #DrugDevelopment #Science #DrugResearch

The research on hydrogen sulfide's therapeutic potential keeps growing... for the latest on its cardioprotective effects, see this recent paper in Cells: mdpi.com/2073-4409/13/2… $ATE.TO $ATBPF #ClinicalTrials #Science #ScienceNews #ScientificResearch #Inflammation

#ClinicalTrials #Science #ScienceNews #ScientificResearch #OpioidCrisis #Inflammation #Pain $ATE.TO $ATBPF

Read the our latest press release here: antibethera.com/news/antibe-re… $ATE.TO $ATBPF #ClinicalTrials #Science #ScienceNews #ScientificResearch #OpioidCrisis #Inflammation #Pain

Positioned as the non-opioid of choice for acute pain, otenaproxesul is headed into its Phase II trial next month – addressing a US $25+ billion market with no novel drugs introduced in 25 years... $ATE.TO $ATBPF #ClinicalTrials #Science #OpioidCrisis #Inflammation #Pain

Beginning with a commercial focus on post-operative pain, we plan to rapidly expand into other acute #pain areas, including acute musculoskeletal pain, dysmenorrhea, migraine, gout, and dental pain. $ATE.TO $ATBPF #Science #ScientificResearch #OpioidCrisis #Inflammation

“With widespread concerns about opioid misuse and addiction, there’s a notable shift towards prioritizing the creation of safer, non-addictive alternatives.” See the full piece featuring Dr. Joe Stauffer, Antibe's CMO: labiotech.eu/in-depth/new-n…. $ATE.TO $ATBPF #OpioidCrisis #Pain

Read the our latest press release here: loom.ly/YY6GvCE $ATE.TO $ATBPF #ClinicalTrials #Science #ScienceNews #ScientificResearch #OpioidCrisis #Inflammation #Pain

To reduce opioid use, widespread use of nonsteroidal anti-inflammatory drugs (NSAIDs) in multimodal analgesia strategies has become standard of care -- otenaproxesul is a next-generation NSAID. $ATE.TO $ATBPF #Science #ScienceNews #OpioidCrisis #Inflammation #Pain

Read the our latest press release here: loom.ly/NA7-tLE $ATE.TO $ATBPF #ClinicalTrials #Science #ScienceNews #ScientificResearch #OpioidCrisis #Inflammation #Pain

Primary market research with U.S. clinicians confirms a high unmet need for safer non-opioid medications for acute pain. $ATE.TO $ATBPF #ClinicalTrials #Science #ScienceNews #ScientificResearch #OpioidCrisis #Inflammation #Pain